These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31267486)

  • 1. NFKBIZ and CW6 in Adalimumab Response Among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis.
    Coto-Segura P; González-Lara L; Batalla A; Eiris N; Queiro R; Coto E
    Mol Diagn Ther; 2019 Oct; 23(5):627-633. PubMed ID: 31267486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NFKBIZ in Psoriasis: Assessing the association with gene polymorphisms and report of a new transcript variant.
    Coto-Segura P; Gonzalez-Lara L; Gómez J; Eiris N; Batalla A; Gómez C; Requena S; Queiro R; Alonso B; Iglesias S; Coto E
    Hum Immunol; 2017; 78(5-6):435-440. PubMed ID: 28259733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.
    Dand N; Duckworth M; Baudry D; Russell A; Curtis CJ; Lee SH; Evans I; Mason KJ; Alsharqi A; Becher G; Burden AD; Goodwin RG; McKenna K; Murphy R; Perera GK; Rotarescu R; Wahie S; Wright A; Reynolds NJ; Warren RB; Griffiths CEM; Smith CH; Simpson MA; Barker JN; ; ;
    J Allergy Clin Immunol; 2019 Jun; 143(6):2120-2130. PubMed ID: 30578879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients.
    Batalla A; Coto E; González-Fernández D; González-Lara L; Gómez J; Santos-Juanes J; Queiro R; Coto-Segura P
    Pharmacogenet Genomics; 2015 Jun; 25(6):313-6. PubMed ID: 25794162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-Cw6 allele, NFkB1 and NFkBIA polymorphisms play no role in predicting response to etanercept in psoriatic patients.
    Caldarola G; Sgambato A; Fanali C; Moretta G; Farina M; Lucchetti D; Peris K; De Simone C
    Pharmacogenet Genomics; 2016 Sep; 26(9):423-7. PubMed ID: 27348478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.
    Talamonti M; Galluzzo M; Zangrilli A; Papoutsaki M; Egan CG; Bavetta M; Tambone S; Fargnoli MC; Bianchi L
    Mol Diagn Ther; 2017 Jun; 21(3):295-301. PubMed ID: 28130758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of IL12B risk haplotype and lack of interaction with HLA-Cw6 among the psoriasis patients in India.
    Chandra A; Senapati S; Ghosh S; Chatterjee G; Chatterjee R
    J Hum Genet; 2017 Mar; 62(3):389-395. PubMed ID: 27829679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis.
    Ryan C; Kelleher J; Fagan MF; Rogers S; Collins P; Barker JN; Allen M; Hagan R; Renfro L; Kirby B
    Clin Exp Dermatol; 2014 Jun; 39(4):519-24. PubMed ID: 24758522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NLRP3 (rs10754558) gene polymorphism and tumor necrosis factor alpha as predictors for disease activity and response to methotrexate and adalimumab in psoriasis.
    Kamel FZ; Hoseiny HAM; Shahawy AAE; Boghdadi G; Shahawy AAE
    BMC Immunol; 2024 Jul; 25(1):40. PubMed ID: 38965465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL17RA gene variants and anti-TNF response among psoriasis patients.
    Batalla A; Coto E; Gómez J; Eirís N; González-Fernández D; Gómez-De Castro C; Daudén E; Llamas-Velasco M; Prieto-Perez R; Abad-Santos F; Carretero G; García FS; Godoy YB; Cardo LF; Alonso B; Iglesias S; Coto-Segura P
    Pharmacogenomics J; 2018 Jan; 18(1):76-80. PubMed ID: 27670766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.
    Talamonti M; Botti E; Galluzzo M; Teoli M; Spallone G; Bavetta M; Chimenti S; Costanzo A
    Br J Dermatol; 2013 Aug; 169(2):458-63. PubMed ID: 23521149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of candidate genes for psoriasis near HLA-C in Chinese patients with psoriasis.
    Chang YT; Tsai SF; Lee DD; Shiao YM; Huang CY; Liu HN; Wang WJ; Wong CK
    Br J Dermatol; 2003 Mar; 148(3):418-23. PubMed ID: 12653732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common and rare CARD14 gene variants affect the antitumour necrosis factor response among patients with psoriasis.
    Coto-Segura P; González-Fernández D; Batalla A; Gómez J; González-Lara L; Queiro R; Alonso B; Iglesias S; Coto E
    Br J Dermatol; 2016 Jul; 175(1):134-41. PubMed ID: 26854129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Variant in the NF-
    Coto-Segura P; Coto E; González-Lara L; Alonso B; Gómez J; Cuesta-Llavona E; Queiro R
    Biomed Res Int; 2019; 2019():1030256. PubMed ID: 31815120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Risk of Psoriasis due to combined effect of HLA-Cw6 and LCE3 risk alleles in Indian population.
    Chandra A; Lahiri A; Senapati S; Basu B; Ghosh S; Mukhopadhyay I; Behra A; Sarkar S; Chatterjee G; Chatterjee R
    Sci Rep; 2016 Apr; 6():24059. PubMed ID: 27048876
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Morelli M; Galluzzo M; Madonna S; Scarponi C; Scaglione GL; Galluccio T; Andreani M; Pallotta S; Girolomoni G; Bianchi L; Talamonti M; Albanesi C
    Expert Opin Biol Ther; 2021 Feb; 21(2):259-270. PubMed ID: 33297781
    [No Abstract]   [Full Text] [Related]  

  • 17. Genetic variants in the NF-κB signaling pathway (NFKB1, NFKBIA, NFKBIZ) and risk of critical outcome among COVID-19 patients.
    Camblor DG; Miranda D; Albaiceta GM; Amado-Rodríguez L; Cuesta-Llavona E; Vázquez-Coto D; Gómez de Oña J; García-Lago C; Gómez J; Coto E
    Hum Immunol; 2022; 83(8-9):613-617. PubMed ID: 35777990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.
    Gallo E; Cabaleiro T; Román M; Solano-López G; Abad-Santos F; García-Díez A; Daudén E
    Br J Dermatol; 2013 Oct; 169(4):819-29. PubMed ID: 23662788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-C and TNF gene polymorphisms are associated with psoriasis in Brazilian patients.
    Cardili RN; Deghaide NS; Mendes-Junior CT; Donadi EA; Souza CS
    Int J Dermatol; 2016 Jan; 55(1):e16-22. PubMed ID: 26470763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKAL1 gene variants affect the anti-TNF response among Psoriasis patients.
    Coto-Segura P; Batalla A; González-Fernández D; Gómez J; Santos-Juanes J; Queiro R; Alonso B; Iglesias S; Coto E
    Int Immunopharmacol; 2015 Dec; 29(2):947-949. PubMed ID: 26563541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.